MedTrace Logo

Treatment Insulin Resistence in HCV G-1 Patient

NCT00546442 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2007-10-19

No results posted yet for this study

Summary

To evaluate the effect of treatment of insulin resistance in the response of chronic hepatitis C treatment, mesure as HCV-RNA negative at week 72.

4.3.2 Objetivos secundarios To evaluate the efficacy and safety of treatment with metformine to erradicate the insulin resistance of patients with chornic hepatitis C genotype 1 measure as HOMA-IR \< 2.

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

Metformine

850-2550 mg/daily for 48 weeks

OTHER

Placebo of metformine

850-2550 mg/daily for 48 weeks

Sponsors & Collaborators

  • Valme University Hospital

    lead OTHER

Principal Investigators

  • Manuel Romero-Gomez, Dr · Hospital Universitario de Valme. Sevilla

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Completion
2007-01-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00546442 on ClinicalTrials.gov